Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bernard Combe

Showing results (41-50 of 282) with videos related to

Pageof 29
Sort By:
Joint Bone Spine|October 11, 2005
The rheumatoid shoulder: current consensus on diagnosis and treatmentThierry Thomas, Eric Noël, Philippe Goupille, et al.
Joint Bone Spine|April 8, 2014
Prevalence and concordance of early and sustained remission assessed by various validated indices in the early arthritis "ESPOIR" cohortIhsane Hmamouchi, Bernard Combe, Bruno Fautrel, et al.
The Journal of Rheumatology|November 19, 2013
Repeated anticitrullinated protein antibody and rheumatoid factor assessment is not necessary in early arthritis: results from the ESPOIR cohortLaure Gossec, Simon Paternotte, Bernard Combe, et al.
Clinical and Experimental Rheumatology|July 7, 2012
Risk of malignancy including non-melanoma skin cancers with anti-tumor necrosis factor therapy in patients with rheumatoid arthritis: meta-analysis of registries and systematic review of long-term extension studiesPierre Le Blay, Gael Mouterde, Thomas Barnetche, et al.
Rheumatology and Therapy|February 28, 2025
The Cardiovascular Safety of Tumour Necrosis Factor Inhibitors in Arthritic Conditions: A Structured Review with RecommendationsJérôme Avouac, Hafid Ait-Oufella, Caroline Habauzit, et al.
The Journal of Rheumatology|April 17, 2017
Triple Oral Therapy Versus Antitumor Necrosis Factor Plus Methotrexate (MTX) in Patients with Rheumatoid Arthritis and Inadequate Response to MTX: A Systematic Literature ReviewJulia Mary, Michel De Bandt, Cédric Lukas, et al.
The Journal of Rheumatology|March 3, 2012
Short-term risk of total malignancy and nonmelanoma skin cancers with certolizumab and golimumab in patients with rheumatoid arthritis: metaanalysis of randomized controlled trialsPierre LE Blay, Gael Mouterde, Thomas Barnetche, et al.
Clinical and Experimental Rheumatology|December 16, 2016
TNF inhibitors increase fat mass in inflammatory rheumatic disease: a systematic review with meta-analysisSarah Marouen, Thomas Barnetche, Bernard Combe, et al.
Rheumatology (Oxford, England)|November 19, 2003
The 5-yr HAQ-disability is related to the first year's changes in the narrowing, rather than erosion score in patients with recent-onset rheumatoid arthritisJean Francis Maillefert, Bernard Combe, Philippe Goupille, et al.
Annals of the Rheumatic Diseases|September 4, 2017
Optimal methotrexate dose is associated with better clinical outcomes than non-optimal dose in daily practice: results from the ESPOIR early arthritis cohortCécile Gaujoux-Viala, Nathalie Rincheval, Maxime Dougados, et al.
Pageof 29

Showing results (41-50 of 282) with videos related to

Sort By:
Pageof 29
Joint Bone Spine|October 11, 2005
The rheumatoid shoulder: current consensus on diagnosis and treatmentThierry Thomas, Eric Noël, Philippe Goupille, et al.
Joint Bone Spine|April 8, 2014
Prevalence and concordance of early and sustained remission assessed by various validated indices in the early arthritis "ESPOIR" cohortIhsane Hmamouchi, Bernard Combe, Bruno Fautrel, et al.
The Journal of Rheumatology|November 19, 2013
Repeated anticitrullinated protein antibody and rheumatoid factor assessment is not necessary in early arthritis: results from the ESPOIR cohortLaure Gossec, Simon Paternotte, Bernard Combe, et al.
Clinical and Experimental Rheumatology|July 7, 2012
Risk of malignancy including non-melanoma skin cancers with anti-tumor necrosis factor therapy in patients with rheumatoid arthritis: meta-analysis of registries and systematic review of long-term extension studiesPierre Le Blay, Gael Mouterde, Thomas Barnetche, et al.
Rheumatology and Therapy|February 28, 2025
The Cardiovascular Safety of Tumour Necrosis Factor Inhibitors in Arthritic Conditions: A Structured Review with RecommendationsJérôme Avouac, Hafid Ait-Oufella, Caroline Habauzit, et al.
The Journal of Rheumatology|April 17, 2017
Triple Oral Therapy Versus Antitumor Necrosis Factor Plus Methotrexate (MTX) in Patients with Rheumatoid Arthritis and Inadequate Response to MTX: A Systematic Literature ReviewJulia Mary, Michel De Bandt, Cédric Lukas, et al.
The Journal of Rheumatology|March 3, 2012
Short-term risk of total malignancy and nonmelanoma skin cancers with certolizumab and golimumab in patients with rheumatoid arthritis: metaanalysis of randomized controlled trialsPierre LE Blay, Gael Mouterde, Thomas Barnetche, et al.
Clinical and Experimental Rheumatology|December 16, 2016
TNF inhibitors increase fat mass in inflammatory rheumatic disease: a systematic review with meta-analysisSarah Marouen, Thomas Barnetche, Bernard Combe, et al.
Rheumatology (Oxford, England)|November 19, 2003
The 5-yr HAQ-disability is related to the first year's changes in the narrowing, rather than erosion score in patients with recent-onset rheumatoid arthritisJean Francis Maillefert, Bernard Combe, Philippe Goupille, et al.
Annals of the Rheumatic Diseases|September 4, 2017
Optimal methotrexate dose is associated with better clinical outcomes than non-optimal dose in daily practice: results from the ESPOIR early arthritis cohortCécile Gaujoux-Viala, Nathalie Rincheval, Maxime Dougados, et al.
Pageof 29